Mirtazapin Hormosan (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine. It also antagonises 5‑HT2, 5‑HT3 and H1 receptors, leading to enhanced serotonergic transmission and antihistaminic effects that together improve mood and sleep patterns.

The dose of mirtazapine is individualized by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. The prescriber determines the appropriate starting dose and any subsequent adjustments.

Safety data for mirtazapine in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when possible. Breastfeeding mothers should discuss potential exposure with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. This mechanism often results in strong sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Mirtazapin Hormosan should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability.

The medication is taken orally, usually once daily in the evening due to its sedative properties. It should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include the potential for suicidal thoughts or behaviors, especially early in treatment, agranulocytosis, severe hypotension, and rare dermatologic reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for any sudden changes in mood, blood counts, or skin condition.

Mirtazapin Hormosan is contraindicated in patients who have taken a monoamine oxidase inhibitor within the past 14 days. Caution is also advised for individuals with uncontrolled cardiovascular disease, severe hepatic impairment, or a history of hypersensitivity to mirtazapine or any excipients.